ERBB2 (HER2) represents one of the most clinically relevant biomarkers in gastric cancer, with approximately 15–20% of gastric and gastroesophageal junction (GEJ) adenocarcinomas demonstrating ERBB2 overexpression or amplification [3]. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.